Analysts Are Bullish on Top Healthcare Stocks: Alnylam Pharma (ALNY), Replimune Group (REPL)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Alnylam Pharma (ALNY – Research Report), Replimune Group (REPL – Research Report) and Eli Lilly & Co (LLY – Research Report) with bullish sentiments.

Alnylam Pharma (ALNY)

In a report released today, Gena Wang from Barclays reiterated a Buy rating on Alnylam Pharma, with a price target of $236.00. The company’s shares closed last Wednesday at $201.90.

According to TipRanks.com, Wang is a 5-star analyst with an average return of 12.5% and a 45.5% success rate. Wang covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Vertex Pharmaceuticals, and Ionis Pharmaceuticals.

Currently, the analyst consensus on Alnylam Pharma is a Moderate Buy with an average price target of $250.79, implying a 22.9% upside from current levels. In a report issued on June 30, Citi also maintained a Buy rating on the stock with a $265.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Replimune Group (REPL)

Barclays analyst Peter Lawson assigned a Buy rating to Replimune Group yesterday and set a price target of $50.00. The company’s shares closed last Wednesday at $20.20.

According to TipRanks.com, Lawson is a 3-star analyst with an average return of 1.7% and a 42.4% success rate. Lawson covers the Healthcare sector, focusing on stocks such as Springworks Therapeutics, Iovance Biotherapeutics, and Arvinas Holding Company.

Replimune Group has an analyst consensus of Strong Buy, with a price target consensus of $54.63, which is a 157.3% upside from current levels. In a report issued on June 27, BTIG also maintained a Buy rating on the stock with a $60.00 price target.

Eli Lilly & Co (LLY)

In a report released yesterday, Carter Gould from Barclays assigned a Buy rating to Eli Lilly & Co, with a price target of $500.00. The company’s shares closed last Wednesday at $440.60.

According to TipRanks.com, Gould is a 3-star analyst with an average return of 2.5% and a 50.3% success rate. Gould covers the Healthcare sector, focusing on stocks such as Reata Pharmaceuticals, Travere Therapeutics, and Merck & Company.

Eli Lilly & Co has an analyst consensus of Strong Buy, with a price target consensus of $478.23, a 9.1% upside from current levels. In a report issued on June 27, J.P. Morgan also maintained a Buy rating on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.